Open an account

Neuropace

NPCE · NASDAQ

$13.51+$0.74 (+5.79%)TodayMarket closed ·
Prev close $12.77

About NPCE

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.

Employees
209
Headquarters
Mountain View, California
Listed
Apr 22, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
neuropace.com

NPCE key statistics

Market cap
463.72M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
125.52K
Volume
116.89K
Open price
$12.84
High today
$13.53
Low today
$12.81
52 Week high
$19.60
52 Week low
$9.22

Neuropace (NPCE) at a glance

As of Oct 20, 2026, Neuropace (NPCE) shares are priced at $13.51, giving the company a market cap of 463.72M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.81 and $13.53. The current price is 5.5% above the day's low and 0.1% below its high.

Volume so far is 116.89K shares, in line with the average of 125.52K shares a day.

Over the past year Neuropace has ranged from $9.22 to $19.60, and now sits 41% of the way up that range.

Neuropace met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.2108.

The average analyst price target is $20.40, 51.0% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $20.40
Low
$18.18
Now
$13.51
High
$23.10

NPCE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 26.6% on average.

  1. Q3 FY24: reported -$0.19 per share against an estimate of -$0.2737
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.2273
  3. Q1 FY25: reported -$0.21 per share against an estimate of -$0.2463
  4. Q2 FY25: reported -$0.26 per share against an estimate of -$0.227
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.2002
  6. Q4 FY25: reported -$0.08 per share against an estimate of -$0.1545
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.2282
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.2108

NPCE news

  • Press releaseBusiness Wire

    NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

  • Press releaseBusiness Wire

    NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

  • Press releaseBusiness Wire

    NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseBusiness Wire

    NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

  • Press releaseBusiness Wire

    NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

  • Press releaseBusiness Wire

    NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

  • NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript

Similar companies

Companies in the same industry as Neuropace

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.